Are we content with lowering blood pressure alone, or should we be asking something more from the antihypertensive drugs we use?: Effects of antihypertensive agents on fibrinolytic function

Journal of Human Hypertension

Volumn 18, Issue 10, 2004, Pages 681-683

  Roldan V ^a   Marin F ^b  

^a Hospital de San Vicente   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; CALCIUM ANTAGONIST; DELAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; MANIDIPINE; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG MECHANISM; FIBRINOLYSIS; HEART INFARCTION; HEMOSTASIS; HUMAN; HYPERTENSION; INFLAMMATION; NON INSULIN DEPENDENT DIABETES MELLITUS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STROKE; SYSTOLIC BLOOD PRESSURE; THROMBOSIS;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; FIBRINOLYSIS; HUMANS;

EID: 5644221793     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001754     Document Type: Article

References (34)

1. Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991; 78: 3114-3124.
2. Murphy G et al. Regulation of matrix metalloproteinase activity. Ann NY Acad Sci 1994; 732: 31-41.
3. Lupu F et al. Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1995; 15 1444-1455.
4. Ross R. Atherosclerosis. An inflammatory disease. N Engl J Med 1999; 340: 115-126.
5. Hamsten A. Hemostatic function and coronary artery disease. N Engl J Med 1995; 332: 677-678.
6. Blann AD, Taberner DA. A reliable marker of endothelial cell dysfunction: does it exist? Br J Haematol 1995; 90: 244-248.
7. Jansson JH, Johansson B, Boman K, Nilsson TK. Hypofibrinolysis in patients with hypertension and elevated cholesterol. J Intern Med 1991; 229: 309-316.
8. Poli KA et al. Association of blood pressure and fibrinolytic potential in the Framingham Offspring Study. Circulation 2000; 101: 264-269.
9. Meigs JB et al. Hyperinsulinemia, hyperglycemia and impaired hemostasis: the Framingham Offsprings Study. JAMA 2000; 283: 221-228.
10. Ridker PM et al. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341 1165-1168.
11. Thompson SG et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-641.
12. Ridker PM et al. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 1994; 343: 940-943.
13. De Bono D. Significance of raised plasma concentrations of tissue-type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease. Br Heart J 1994; 71: 504-507.
14. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19: 972-978.
15. Lip GYH. Hypertension, platelets, and the endothelium. The "thrombotic paradox of hypertension" (or Birmingham paradox) revisited. Hypertension 2003; 41: 199-200.
16. Lip GYH, Blann AD. Does hypertension confer a prothrombotic state? Virchow's triad revisited. Circulation 2000; 101: 218-220.
17. Lee AJ. The role of rheological and haemostatic factors in hypertension. J Hum Hypertens 1998; 11: 767-776.
18. Mugellini A et al. Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus. J Hum Hypertens 2004; 18: 687-691.
19. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. J Clin Invest 1995; 95: 995-1001.
20. Nakamura S et al. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type I receptor in vivo. Kidney Int 2000; 58: 251-259.
21. Brown NJ, Agirbasli M, Vaughan DE. Comparative effect of angiotensin enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Hypertension 1999; 34: 285-290.
22. Felmeden DC, Lip GYH. The rennin-angiotensin-aldosterone system and fibrinolysis. J RAAS 2000; 1: 240-244.
23. Brown NJ, Kumar S, Painter CA, Vaughan DE. ACE inhibition versus antigiotensin type 1 receptor antagonism. Differential effects on PAI-1 over time. Hypertension 2002; 40: 859-865.
24. Fogari R et al. Effect of benazepril amlodipine combination on fibrinolysis in hypertensive diabetic patients. Eur J Clin Pharmacol 2003; 59: 271-275.
25. Sakata K et al. Differential effects of enalapril and nitrendipine on the fibrinolytic system in essential hypertension. Am Heart J 1999; 137: 1094-1099.
26. Pahor M et al. Fosinopril versus amlodipine comparative treatments study. A randomized trial to assess effects on plasminogen activator inhibitor-1. Circulation 2002; 105: 457-461.
27. Vuorinen-Markkola H, Yki-Jarvinen H. Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus. Metabolism 1995; 44: 85-89.
28. Libby PL, Simon DI. Inflammation and thrombosis. The clot thickens. Circulation 2001; 103: 1718-1720.
29. Blann AD, Naqvi T, Waite M, McCollum CN. Von Willebrand factor and endothelial damage in essential hypertension. J Hum Hypertens 1993; 7: 107-111.
30. Bautista LE. Inflammation, endothelial dysfunction, and the risk of high blood pressure: epidemiologic and biological evidence. J Hum Hypertens 2003; 17: 223-230.
31. Blann AD, Nadar S, Lip GYH. Pharmacological modulation of platelet function in hypertension. Hypertension 2003; 42: 1-7.
32. Nadar S, Lip GYH. The prothrombotic state in hypertension and the effects of antihypertensive treatment. Curr Pharm Des 2003; 9: 1715-1732.
33. Lindholm LH et al. Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. Lancet 2003; 359: 1004-1010.
34. Chong AY, Lip GYH. LIFE: losartan versus atenolol. Lancet 2003; 362: 1416.